Shankar Musunuri
-
Malvern Gene Company to Raise $115M from Convertible Notes While Dealing with Stock Decline
Malvern-based Ocugen saw its stock fall almost 20 percent after an announcement to use convertible notes to pay down existing debt and fund ongoing drug…
-
Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy
Malvern-based Ocugen has been granted rare pediatric disease designation by the Food and Drug Administration for its experimental gene therapy targeting Stargardt disease, writes John…
-
Malvern’s Ocugen Finalizes Reverse Merger, Begins ‘New Chapter’ as a Publicly Traded Company
Ocugen, a gene therapy and biopharmaceutical company in Malvern, has finalized its reverse merger with Histogenics, a publicly traded company in Boston, and is now…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
